Literature DB >> 16155918

Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.

Dubravka S Cvejic1, Svetlana B Savin, Ivana M Petrovic, Ivan R Paunovic, Svetislav B Tatic, Marija J Havelka.   

Abstract

BACKGROUND: Galectin-3 has been recently recognized as a promising presurgical marker of thyroid malignancy.
METHODS: Galectin-3 expression was examined immunohistochemically in 202 specimens of papillary thyroid carcinoma (PTC) in relation to histomorphologic subtypes and clinicopathologic data. RESULTS.: The sensitivity of galectin-3 immunostaining versus conventional histology was 98% (100 of 102) for classical PTC, 85.2% (46 of 54) for follicular variant, and 50% (23 of 46) for follicular/solid variant of PTC. All cases (n = 36) involving lymph node metastases and 42 of 45 cases with extrathyroid invasion expressed galectin-3. However, among the galectin-3-positive cases (n = 169), 133 were without lymph node metastases, and 127 were without extrathyroid invasion. Galectin-3 expression was not related to the size of intrathyroid PTC.
CONCLUSIONS: Galectin-3 immunohistochemical expression itself is not an indicator of local metastatic spread or extrathyroid invasion of PTC, thus being irrelevant clinically from this aspect. Galectin-3 is an excellent marker for classical PTC but must be used with caution in diagnosing unconventional variants of PTC because of the possibility of false-negative results. (c) 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155918     DOI: 10.1002/hed.20276

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

Review 1.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.

Authors:  Sonja A Selemetjev; Svetlana B Savin; Ivan R Paunovic; Svetislav B Tatic; Dubravka Cvejic
Journal:  Wien Klin Wochenschr       Date:  2014-12-04       Impact factor: 1.704

3.  Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma.

Authors:  Hüseyin K Türköz; Hülya Oksüz; Ziya Yurdakul; Deniz Ozcan
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

Review 5.  Controversies in thyroid pathology: the diagnosis of follicular neoplasms.

Authors:  Stefano Serra; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

6.  Serum Galectin-3: diagnostic value for papillary thyroid carcinoma.

Authors:  Erdem Yılmaz; Tamer Karşıdağ; Cihad Tatar; Sefa Tüzün
Journal:  Ulus Cerrahi Derg       Date:  2015-04-09

Review 7.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.